Woman Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
to compare the investigator assessed progression-free survival (PFS) following treatment with single agent neratinib versus lapatinib plus capecitabine in subjects with erbB2 positive locally advanced or metastatic breast cancer.
Inclusion criteria
- Locally advanced or metastatic breast cancer